Novo Nordisk has presented post hoc analysis of data from a trial sub-population with 55 participants, showing that Wegovy (pooled semaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without diabetes.
Change in percentage of liver fat, determined by magnetic resonance imaging (MRI), showed that mean liver fat in the group taking semaglutide declined from 8.8% at baseline to 3.1% at week 72.
In addition, the analysis showed that 26 participants entered the trials with liver fat above 5% and 88.5% of them – 23 participants – reached the below-5% threshold by week 72, bringing their liver fat to normal levels.
The findings are presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 in Milan, Italy.
